Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder

NCT00139919 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Schizoaffective Disorder
Bipolar Disorder

Interventions

DRUG: Bifeprunox

Sponsor

Solvay Pharmaceuticals

Collaborators

[object Object]
[object Object]